Whitepaper: Detecting CAR-T cells using Fluorokines™
This article outlines the advantages of using R&D Systems™ fluorescent-labeled proteins to directly stain and detect CAR+ cells by flow cytometry.
List view / Grid view
This article outlines the advantages of using R&D Systems™ fluorescent-labeled proteins to directly stain and detect CAR+ cells by flow cytometry.
A powerful tool to study complex phenotypes and cellular interactions. Map spatial interactions twice as fast with this second-generation system.
31 August 2022 | By Eurofins Discovery
Watch our on-demand webinar where our expert speaker will explore the possibilities for designing selective small molecules targeting the SH2 domains of STAT proteins plus more.
Application note: Quantifying T Cell response in 3D tumour spheroids using advanced flow cytometry workflows.
19 August 2022 | By Sartorius
Want to learn about the latest research and development of cell models in rare diseases? Then watch this virtual panel discussion to hear from industry experts.
This publications review overviews advanced flow cytometry applications in infectious disease and immuno-oncology.
Learn about current and emerging immune checkpoint molecules that are being investigated as potential immuno-oncology targets.
This guide highlights the four major stages of TPD, the challenges at each step and questions you should ask yourself.
Learn about DLS, a powerful method to characterise the purity and aggregation state of your biologics for improved candidate selection.
R&D Systems offers custom antibody production services to engineer the right antibody to solve your research question with confidence.
Join leading experts as they discuss the wide range of uses for CRISPR, including for therapeutics and biomanufacturing.
This whitepaper overviews how high throughput, multi-parametric analysis accelerates antibody discovery workflows.
Single-domain antibodies (sdAb) are small, stable antibodies derived from camelids with a single monomeric variable domain.
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
Scientists have received approval to work with a weakened, non-harmful version of SARS-CoV-2 in biosafety level 2 laboratories, which makes it more efficient to study the virus, and to identify new treatments.